Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | LDHA | P00338 | 2/20 | 0.34 |
| ▸ | LCAT | P04180 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869638 | 0.77 | GPR119 (0.38) | GPR119GPR183LDHALCATKMT2A | |
| SCHEMBL1103828 | 0.73 | GPR119 (0.43) | GPR119GPR183LCATKMT2ALMNA | |
| SCHEMBL384433 | 0.69 | GPR119 (0.63) | GPR119GPR183 | |
| SCHEMBL1103825 | 0.66 | CHRM3 (0.44) | GPR119LDHALCAT | |
| SCHEMBL11956862 | 0.66 | CHRM3 (0.45) | GPR119LCAT | |
| SCHEMBL1092840 | 0.64 | GPR119 (0.46) | GPR119GPR183KMT2ALMNAHTT | |
| SCHEMBL3694402 | 0.63 | GPR119 (0.59) | GPR119LCAT | |
| SCHEMBL15666079 | 0.62 | GPR119 (0.59) | GPR119GPR183 | |
| SCHEMBL15495649 | 0.62 | GPR119 (0.52) | GPR119GPR183 | |
| SCHEMBL15511176 | 0.62 | GPR119 (0.52) | GPR119GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885KDM1A 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.